Integrated CLD with Coordinated. GMP Manufacturing

One Seamless Path from Gene to Clinical Material

Demeetra’s integrated service connects cell line development (CLD) directly to upstream process development and GMP manufacturing, without rebuilds, relicensing, or vendor handoff delays.

Powered by our CleanCut™ CHO platforms and Harbor-IN™ transposase technology, we generate stable, high-titer cell lines built for seamless transition into GMP manufacturing.

From gene to clinical material. One partner. One path.

Eliminate Rebuilds. Eliminate Re-Qualification. Eliminate Friction.

Traditional development models fragment CLD and manufacturing across multiple vendors and technology systems. The results often include:

  • Cell line reconstruction due to licensing limitations
  • Re-qualification and comparability studies
  • Technology transfer delays
  • FTO gaps discovered late in development
  • Added regulatory risk and cost

Demeetra removes those barriers.

Our integrated model enables partners to advance the exact same production-ready cell lines generated during CLD directly into upstream development and GMP manufacturing delivered in collaboration with NorthX Biologics. With more than 30 years of GMP experience, NorthX provides process development, analytics, biomanufacturing, and aseptic fill-finish services from its facilities in Sweden, supporting clinical and commercial-stage biologics manufacturing.

From gene to clinical material. One coordinated path.

The Demeetra Integrated Advantage

CleanCut™ CHO Platforms

CleanCut CHO systems are engineered using the Cas-CLOVER gene editng system to support robust expression, genetic stability, and manufacturability from day one.

Harbor-IN™ Transposase

Efficient, stable genomic integration technology that supports consistent, high-quality cell line generation. Engineered to minimize downstream licensing obligations and reduce freedom-to-operate risks as programs advance toward commercialization.

Manufacturing-Ready by Design

Cell lines are developed with downstream GMP advancement in mind, supported by full characterization, documented cell history, and analytical testing to ensure validated clones remain viable for clinical manufacturing.

One Continuous Development Strategy

Discovery → CLD → Upstream Development → GMP Manufacturing

Instead of transferring between disconnected systems or switching editing platforms before commercialization, our partners advance the exact same characterized cell lines into GMP production.

This enables:
  • Faster IND-enabling timelines
  • Reduced comparability risk
  • Lower overall development cost
  • Preserved asset value
  • A clearer regulatory narrative

Your molecule stays on a single, coherent development path – technically, strategically, and with clear freedom to operate.

Protecting What Matters Most

Demeetra’s integrated CLD-to-GMP solution is designed to safeguard the core drivers of program success as you advance toward clinical manufacturing:

  • Your timeline.
  • Your regulatory position.
  • Your freedom to operate.
  • Your asset value.

Built for Emerging and Established Biopharma

Whether you are advancing your first biologic or expanding a multi-asset pipeline, our integrated model provides:

  • Reduced vendor complexity

  • Fewer technical hurdles

  • Greater process continuity
  • Clean IP positioning across development and manufacturing
  • A streamlined partnership structure

Start with the End in Mind

Manufacturing should not require starting over. With Demeetra’s Integrated Cell Line Development to GMP Manufacturing service, your program advances on a single, continuous technical and licensing foundation.

Let’s build your next clinical asset on an integrated path that protects both time and value.